Galderma's Mirvaso wins FDA nod to reduce rosacea redness
This article was originally published in Scrip
Executive Summary
The FDA granted approval on 26 August to Galderma Laboratories' topical gel product Mirvaso (brimonidine) as a once-daily treatment for adults 18 years or older to reduce the redness of rosacea, also known as facial erythema.